GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,590.00
Bid: 12,590.00
Ask: 12,596.00
Change: 74.00 (0.59%)
Spread: 6.00 (0.048%)
Open: 12,566.00
High: 12,632.00
Low: 12,512.00
Prev. Close: 12,516.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: FTSE 100 flat, peers and pound up before US data

Thu, 10th Aug 2023 11:59

(Alliance News) - London's FTSE 100 underwhelmed on Thursday, as a slew of its heavyweights went ex-dividend, though blue-chip equities in mainland Europe were higher, showing no signs of pre-US inflation data angst and overlooking an acceleration in tensions between the world's two largest economies.

The FTSE 100 index went into Thursday afternoon just 3.58 points lower at 7,583.72. The FTSE 250 was down just 4.05 points at 18,933.15, and the AIM All-Share was down 1.69 points, 0.2%, at 756.29.

The Cboe UK 100 was up 0.1% at 756.47, the Cboe UK 250 was up 0.3% at 16,637.94, and the Cboe Small Companies was up 0.1% at 13,610.77.

In European equities on Thursday, the CAC 40 in Paris was up 0.8%, while the DAX 40 in Frankfurt was 0.3% higher.

Ahead of the US inflation data reported at 1330 BST, the dollar was largely weaker.

The pound was quoted at USD1.2772 early Thursday afternoon in London, climbing from USD1.2717 at the London equities close on Wednesday. The euro traded at USD1.1027, up from USD1.0977. Against the yen, the dollar rose to JPY143.80, from JPY143.60.

According to FXStreet cited consensus, the US annual inflation rate is expected to heat up to 3.3%, from 3.0% in June. The core inflation rate, which excludes food and energy, is expected to remain at 4.8%.

"The last reading provided a positive surprise as it undershot expectations for the first time in a long time. A repeat could revive a flagging equity rally, but a negative shock could accelerate recent selling," AJ Bell analyst Russ Mould commented.

A hotter-than-expected reading could mean the Federal Reserve continues with its hiking cycle.

Oanda analyst Craig Erlam commented: "It will take something big for the Fed to consider hiking again you would think, having shifted to a more gradual approach in recent months."

In London, share price falls of 1.2% and 1.3% for lenders HSBC and NatWest, 1.1% for drugmaker AstraZeneca and 3.0% for miner Rio Tinto hurt the FTSE 100. The stocks went ex-dividend, meaning new buyers do not qualify for the latest payouts.

Spirax-Sarco fell 5.0%, sitting at the bottom of the large-cap index.

The Cheltenham, England-based thermal energy management and pumping company said pretax profit fell 18% to GBP114.0 million, from GBP138.5 million a year ago.

The firm reported revenue of GBP850.8 million in the first half of 2023, up 13% from GBP750.1 million the year prior.

Spirax warned destocking in Biopharm, which refers to sales from the Watson-Marlow division to pharma and biotech, "is now expected to continue into 2024".

Looking ahead, the company said it expects its revenue group sales to be between flat and 4% higher for the year, when compared to 2022's pro-forma sales of GBP1.73 billion. Back in a May trading update, it predicted "double-digit sales growth for the group in 2023, representing mid-single-digit sales growth over 2022 pro-forma sales".

Savills slumped 8.7% as it reported a decline in first-half earnings.

The estate agent said pretax profit in the half-year ended June 30 plunged 88% to GBP6.0 million from GBP50.4 million 12 months earlier. Revenue declined 2.5% to GBP1.01 billion from GBP1.04 billion.

Chief Executive Mark Ridley said: "Savills has weathered both the inflationary cost conditions and reduced transaction volumes well, increasing market share and, supported by our strong balance sheet, continuing to undertake selective business development activities to further the group's long term growth strategy. We are seeing some positive signs in markets such as the UK and continued strength in certain Asia Pacific markets including Japan; in Continental Europe and mainland China we now expect reduced market volumes to continue through much of the year."

Elsewhere in London, Eco Atlantic jumped 12%, as it struck a deal to buy Tullow Oil's stake in a block in Guyana. Tullow was 1.2% higher.

Oil and gas explorer Eco will buy an additional 60% stake in the Orinduik block and will hold 75% as a result. TOQAP Guyana, a joint venture between TotalEnergies and QatarEnergy owns the remainder. Tullow no longer has a stake.

Eco Atlantic will pay USD700,000 to Tullow upfront, USD4 million in the event of commercial discovery and USD10 million upon the issue of a production licence from the government of Guyana. In addition, Tullow will have a royalty on future output.

Analysts at Peel Hunt commented: "We see this as a good deal for both parties, as it allows Tullow to continue to focus on its strategy of monetising its high-quality production assets with continued exposure to Guyana upside, while exploration-focused Eco has picked up a material stake in this high-potential licence for a relatively small upfront consideration. The deal also gives Eco additional optionality with regards bringing a new partner into the licence."

Stocks in New York are called to open higher on Thursday. Both the Dow Jones Industrial Average and S&P 500 are called up 0.5%, and the Nasdaq Composite 0.6% higher.

Beijing hit back on Thursday after the US restricted investments in Chinese technology.

US President Joe Biden hours earlier announced an executive order directing the Treasury Department to restrict certain US investments in China in sensitive high-tech sectors including semiconductors, quantum computing and artificial intelligence.

China's foreign ministry blasted the move as an attempt to "engage in anti-globalisation and de-sinicisation", warning that China would "resolutely safeguard its own rights and interests".

Analysts at UBS commented: "We expect tensions in the US-China bilateral relationship to remain elevated. A regime of increasing restrictions on technology transfer and capital flows between the two nations is likely to take hold and become a persistent irritant."

Gold was quoted at USD1,922.05 an ounce early Thursday afternoon, rising from USD1,916.66 on Wednesday. Brent oil was trading at USD87.38 a barrel, higher than USD86.92.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.